For Oncology Scientific Educational Exchange (OSEE 2021): New Developments in Pediatric Neuro-Oncology, Dr. Stefan M. Pfister will discuss opportunities and challenges associated with the diagnosis and treatment of childhood brain tumors including implications from the 2021 WHO classification of CNS tumors and from recent regulatory changes in pediatric drug development.
Nov 9, 2021 8 to 9 AM in Amsterdam, Berlin, Rome, Stockholm, Vienna
Join renowned pediatric neuro-oncologist Stefan Pfister, MD, on innovative treatments of childhood brain tumors in this in-depth discussion.
FEATURED SPEAKER
Stefan Pfister, MD
Oncologist at the Hopp Children´s Cancer Center at the NCT Heidelberg (KiTZ)
HOSTED BY
Mark Rubin, MD
Professor, Principal Investigator, and Director of the Department for BioMedical Research (DBMR), University of Bern, Switzerland
Mark A. Rubin
Mark A. Rubin, MD, Professor, Principal Investigator, and Director of the Department for BioMedical Research (DBMR), University of Bern, Switzerland. Prof. Mark Rubin is a recognized world-renown leader in prostate cancer genomics and pathology, and precision medicine. Dr. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Furthermore, Prof.
Stefan M Pfister
Stefan Pfister serves as Director of the Preclinical Research Program of the new Hopp Children's Cancer Center Heidelberg, a joint venture between the German Cancer Research Center (DKFZ) and Heidelberg University Hospital. He is heading the Division Pediatric Neurooncology at the German Cancer Research Center (DKFZ) since 2012. Being a pediatrician by training, Pfister received his MD from Tübingen University, and his clinical education at Mannheim and Heidelberg University Hospitals.